Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
Up to 40% of individuals with alcohol use disorder (AUD) experience depression, which increases the risk of early relapse. Depression can cause relapse to occur 3 times faster in individuals with AUD who experience depressive symptoms at discharge. No treatments have been approved for individuals with both AUD and depression. (The sponsor's summary, shortened.)
Eligibility and contacts on ClinicalTrials.govThe registry record
- Status
- Recruiting
- Phase
- Phase 3
- Conditions
- Alcohol Use Disorder; Depressive Sympotoms; Psilocybin
- Intervention
- Psilocybin (high dose); Psilocybin (low dose)
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Ages
- 18 Years and over
- Sex
- All
- Healthy volunteers
- No
- Enrolment
- 172 people (planned)
- Start
- 30 June 2026
- Primary completion
- June 2030
- Registry last updated
- 1 July 2026
Sites (8)
- Centre Hospitalier de la Côte Basque, Bayonne, France (not yet recruiting)
- CHU Besançon, Besançon, France (not yet recruiting)
- CHU de Bordeaux, Bordeaux, France (not yet recruiting)
- CHU Brest, Brest, France (not yet recruiting)
- CH Le Vinatier, Bron, France (not yet recruiting)
- CHU de Nantes, Nantes, France (not yet recruiting)
- CHU de Nîmes, Nîmes, France (recruiting)
- CHU Saint-Etienne, Saint-Priest, France (not yet recruiting)
How joining a trial works
- Free to take part
- Trials generally cost participants nothing for the study drug and the study visits, and some pay for travel or time. Check what a study covers on its registry page.
- Screened first
- Every study screens volunteers with questionnaires, medical history and often a physical and psychiatric check. Many people who apply are not enrolled.
- Eligibility is strict
- Common exclusions include a personal or family history of psychosis or bipolar disorder, some heart conditions, pregnancy and certain medications, which you may be asked to stop under medical supervision. Never stop a medication on your own to qualify.
- You may get a placebo
- Many trials compare psilocybin with a placebo or a low dose, and you may not be told which you had until the study ends.
- Contact the study team through the registry
- Each registry record lists the study contacts and sites. We do not republish personal emails or phone numbers; use the link on each trial page.
- Not medical advice
- This is a list of registry records, not a recommendation. Talk to your doctor before applying. Disclaimer · Safety and medications
Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine, read 28 October 2026. Filter: overall status RECRUITING or NOT_YET_RECRUITING; an intervention named psilocybin, psilocin, COMP360 or CYB003. Refreshed weekly; a study's own registry page is always the current record.
Record read from ClinicalTrials.gov API v2, U.S. National Library of Medicine on 28 October 2026. All psilocybin trials